![](https://investorshub.advfn.com/uicon/350406.png?cb=1547729749)
Sunday, March 26, 2017 7:12:19 PM
So let's start on the P&L statement, revenues were $2.3 million for the quarter and $8.3 million for the nine months ended December 31, 2016 and that's compared to $2.2 million and $7.3 million for the quarter and nine months of the prior-year. That's a 6% increase for the quarter as compared to last year and a 13% increase for the year-to-date as compared to last year. These are solid revenue numbers.
Moving down the P&L statement, operating expenses where we had research and development cost of $1.5 million for the quarter and $4.3 million for the nine months ended December 31, 2016. That's down from $3.2 million and $10 million for the comparable periods of the prior-year.
One last point on the P&L statement and that would be the general and administrative expense line item which was essentially unchanged year-to-year. G&A expenses were 700,000 and 2.1 million for the quarter and nine months ended December 31, 2016 this year and this is virtually unchanged from the 700,000 and 2 million in G&A expenses in the prior-year.
I won't talk too much about G&A expenses usually but the takeaway here is that revenues are growing, product development activities continue, new products are being file and trials and bio studies ongoing and all of that is being managed within the same overhead structure. We're always looking to cut costs and be more efficient and here is the metric that demonstrates we are getting more out of our overheads than ever before.
Fear Uncertainty and Doubt FUD It Ain't Going To Work Here Anymore. Notice the lack of question mark.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 08:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 09:30:05 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/31/2023 08:20:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2023 08:15:16 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM